Cowen Inc’s Atara Biotherapeutics ATRA Stock Holding History

Cowen Inc’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-140	Closed	-$129	–	508
2018 Q2	$129	Buy	+140	New	+$150K	0.01%	351

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cowen Inc's ATRA Position: Q3 2018 in Review

Cowen Inc sold out of Atara Biotherapeutics (ATRA) in Q3 2018, closing a stake of 140 shares — an estimated $129 sold.

Cowen Inc first reported a position in ATRA in Q2 2018 and held it in 1 quarter. The position peaked at $129 in Q2 2018. 115 funds tracked by Wall St. Rank hold ATRA as of Q3 2018.

Cowen Inc reported no remaining Atara Biotherapeutics position as of Q3 2018 after selling out during the quarter.
Cowen Inc sold 140 Atara Biotherapeutics shares in Q3 2018, an estimated $129.
Cowen Inc first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 1 quarter.
Cowen Inc's Atara Biotherapeutics position peaked at $129 in Q2 2018.
115 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2018.

Based on Cowen Inc's 13F filing for Q3 2018, filed 13 Nov 2018.